Multitargeted antiangiogenic tyrosine kinase inhibitors combined to chemotherapy in metastatic breast cancer: A systematic review and meta-analysis

European Journal of Clinical Pharmacology

Volumn 70, Issue 5, 2014, Pages 531-538

  Wang, Zexing ^a,b   Wang, Meiqi ^c   Yang, Fei ^c   Nie, Weiwei ^d   Chen, Fengxia ^a   Xu, Jing ^a   Guan, Xiaoxiang ^a,d  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b WANNAN MEDICAL COLLEGE   (China)

^c Department of Critical Care Medicine Wangjiang People's Hospital   (China)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Efficacy; Meta analysis; Metastatic breast cancer; Multitargeted antiangiogenic TKI; Safety

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BRIVANIB; CAPECITABINE; CEDIRANIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; MOTESANIB; NINTEDANIB; PACLITAXEL; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; SORAFENIB; SUNITINIB; VANDETANIB; ANGIOGENESIS INHIBITOR; PROTEIN TYROSINE KINASE;

ABDOMINAL PAIN; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; META ANALYSIS; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; STOMATITIS; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; ENZYMOLOGY; FEMALE; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROTEIN-TYROSINE KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84898890434     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1654-5     Document Type: Review

References (36)

1. Forouzanfar MH, Foreman KJ, Delossantos AM et al (2011) Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 378(9801):1461-1484
2. Cardoso F, Harbeck N, Fallowfield L et al (2012) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(7):vii11-19
3. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(6 Suppl 16):15-18
4. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011-1027
5. Foekens JA, Peters HA, Grebenchtchikov N et al (2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61(14):5407-5414
6. Relf M, LeJeune S, Scott PA et al (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57(5):963-969
7. Miles DW, Dieras V, Cortes J et al (2013) First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 24(11):2773-2780
8. Rossari JR, Metzger-Filho O, Paesmans M et al (2012) Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence. J Oncol. doi: 10.1155/2012/417673
9. Martin M, Roche H, Pinter T et al (2011) Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 12(4):369-376
10. Baselga J, Segalla JG, Roche H et al (2012) Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 30(13):1484-1491
11. Crown JP, Dieras V, Staroslawska E et al (2013) Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 31:2870-2878
12. Boer K, Lang I, Llombart-Cussac A et al (2012) Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study. Invest New Drugs 30(2):681-687
13. Xiao YY, Zhan P, Yuan DM et al (2013) Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 69(2):151-159
14. Gianni L, Romieu GH, Lichinitser M et al (2013) AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 31(14):1719-1725
15. Baker H (2013) 2013 San Antonio Breast Cancer Symposium. Lancet Oncol. doi: 10.1016/S1470-2045(13)70594-1
16. Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16
17. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815-2834
18. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177-188
19. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088-1101
20. Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629-634
21. Rugo HS, Stopeck AT, Joy AA et al (2011) Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 29(18):2459-2465
22. Bergh J, Bondarenko IM, Lichinitser MR et al (2012) First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 30(9):921-929
23. Gradishar WJ, Kaklamani V, Sahoo TP et al (2013) A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer 49(2):312-322
24. Schwartzberg LS, Tauer KW, Hermann RC et al (2013) Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res 19(10):2745-2754
25. Valachis A, Polyzos NP, Patsopoulos NA et al (2010) Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 122(1):1-7
26. Liang W, Zhang L (2013) Multitargeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 31(suppl; abstr 8089)
27. Zhang X, Yang XR, Huang XW et al (2012) Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 11(5):458-466
28. Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931-1939
29. Fukumura D, Jain RK (2007) Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 74(2-3):72-84
30. Baselga J, Costa F, Gomez H et al (2013) A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. Trials 14:228
31. Zhu X, Stergiopoulos K, Wu S (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 48(1):9-17
32. Qi WX, He AN, Shen Z et al (2013) Incidence and Risk of hypertension with a novel multitargeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol 76(3):348-357
33. Nardone B, Hensley JR, Kulik L et al (2012) The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol 11(11):e61-65
34. Chu D, Lacouture ME, Fillos T et al (2008) Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 47(2):176-186
35. Rosen AC, Wu S, Damse A et al (2012) Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab 97(4):1125-1133
36. Wang Z, Xu J, Nie W et al (2013) Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. doi: 10.1007/s00228-013-1598-1